Cancers,
Год журнала:
2024,
Номер
16(16), С. 2848 - 2848
Опубликована: Авг. 15, 2024
Pancreatic
cancer
is
a
significant
challenge
in
oncology
due
to
its
aggressive
nature
and
complex
management,
leading
high
mortality
rates
dismally
low
5-year
survival
rate.
Approximately
85%
of
cases
manifest
as
adenocarcinoma,
while
endocrine
tumors
constitute
less
than
5%.
Borderline
resectable
locally
advanced
pancreatic
cancers
are
particularly
difficult
treat
vascular
involvement,
which
complicates
complete
resections
increases
morbidity.
Various
therapeutic
modalities
aim
overcome
these
challenges
improve
patient
outcomes.
Traditionally,
upfront
surgery
was
the
standard
for
tumors,
with
multimodal
chemotherapy
being
central
treatment.
Understanding
surgical
anatomy
pivotal
enhancing
outcomes
survival.
Resectability
several
when
seeking
achieve
R0
resections,
borderline
tumors.
classification
systems-the
MD
Anderson
criteria,
NCCN
AHPA/SSAT/SSO
consensus
statement,
Alliance
definition-assess
tumor
involvement
major
blood
vessels,
first
systems
broadly
accepted.
Vascular
staging
integration
also
important,
Ishikawa
system
using
preoperative
imaging
assess
venous
involvement.
Furthermore,
neoadjuvant
therapy
enhances
treatment
effectiveness
by
addressing
micro-metastatic
disease
early,
increasing
resection
chances,
downstaging
optimal
surgery.
Insights
from
Fox
Chase
Cancer
Center's
approach
highlight
importance
multidisciplinary
strategy
advancing
improving
prognosis.
This
commentary,
inspired
Dr.
Sanjay
S.
Reddy's
Keynote
Conference
during
MedNews
week,
highlights
current
advancements
ongoing
cancer,
emphasizing
need
comprehensive,
Pancreatic
cancer
is
among
the
most
immune-resistant
tumor
types
due
to
its
unique
microenvironment
and
low
immunogenicity.
Single-agent
immune
modulators
have
thus
far
proven
clinically
ineffective.
However,
a
growing
body
of
evidence
suggests
that
combination
these
with
other
strategies
could
unlock
potential
immunotherapy
in
pancreatic
cancer.
Herein,
we
describe
case
59-year-old
male
metastatic
ductal
adenocarcinoma,
referred
our
center
receive
(serplulimab,
novel
anti-PD-1
antibody)
combined
chemotherapy
(gemcitabine/nab-paclitaxel).
During
initial
three
treatment
cycles,
patient
was
assessed
as
having
stable
disease
(SD)
according
RECIST
1.1
criteria.
following
two
additional
cycles
therapy,
primary
mass
increased
from
4.9
cm
13.2
cm,
accompanied
by
development
new
lung
lesions,
ascites,
pelvic
metastases.
He
succumbed
respiratory
failure
one
month
later.
Retrospective
analysis
revealed
had
MDM4
amplification,
identified
high-risk
factor
for
hyperprogressive
(HPD).
To
knowledge,
this
first
reported
HPD
multiple
metastases
treated
using
therapy.
We
investigated
mechanisms
reviewed
latest
literature
on
predictive
factors
HPD.
These
findings
suggest
while
may
hold
promise
treating
cancer,
it
imperative
identify
closely
monitor
patients
when
immunotherapy.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(21), С. 6419 - 6419
Опубликована: Окт. 26, 2024
Pancreatic
ductal
adenocarcinoma
(PDAC)
is
an
aggressive
malignancy
with
limited
effective
therapeutic
options.
Due
to
a
variety
of
cancer
cell-intrinsic
factors,
including
KRAS
mutations,
chemokine
production,
and
other
mechanisms
that
elicit
dysregulated
host
immune
response,
PDAC
often
characterized
by
poor
infiltration
immune-privileged
fibrotic
stroma.
As
understanding
the
tumor
microenvironment
(TME)
evolves,
novel
therapies
are
being
developed
target
immunosuppressive
mechanisms.
Immune
checkpoint
inhibitors
have
efficacy
when
used
alone
or
radiation.
Combinations
therapies,
along
chemotherapy
chemoradiation,
demonstrated
promise
in
preclinical
early
clinical
trials.
Despite
dismal
response
rates
for
immunotherapy
metastatic
PDAC,
neoadjuvant
somewhat
encouraging,
suggesting
incorporation
treatment
should
be
earlier
disease
course.
Precision
therapy
may
informed
advances
transcriptomic
sequencing
can
identify
immunophenotypes,
allowing
more
appropriate
selection
each
individual
patient.
Personalized
antigen-specific
increasing
topic
interest,
adjuvant
using
personalized
mRNA
vaccines
prevent
recurrence.
Further
development
will
need
balance
precision
generalizability
cost.
Expert Opinion on Pharmacotherapy,
Год журнала:
2024,
Номер
25(1), С. 79 - 90
Опубликована: Янв. 2, 2024
Introduction
Immune
checkpoint
inhibitors
(ICIs)
targeting
programmed
cell
death
protein-1
(PD-1/PD-L1)
pathway
as
well
cytotoxic
T-lymphocyte-associated
protein
4
(CTLA-4)
have
demonstrated
substantial
potential
in
several
malignancies.
Pancreatic
adenocarcinoma
(PC)
still
carries
a
high
mortality
despite
tremendous
advances
the
anti-cancer
arsenal.
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Апрель 10, 2024
Currently,
there
are
no
studies
showing
which
neoadjuvant
therapy
modality
can
provide
better
prognosis
for
patients
after
pancreatic
cancer
surgery.
This
study
explores
the
optimal
model
by
comparing
survival
differences
between
with
non-metastatic
(cT1-4N0-1M0)
who
received
chemotherapy
(NACT)
and
chemoradiotherapy
(NARCT).
Pharmaceuticals,
Год журнала:
2024,
Номер
17(8), С. 991 - 991
Опубликована: Июль 26, 2024
The
knowledge
surrounding
the
application
of
immune
checkpoint
inhibitors
(ICIs)
in
treatment
pediatric
cancers
is
continuously
expanding
and
evolving.
These
therapies
work
by
enhancing
body's
natural
response
against
tumors,
which
may
have
been
suppressed
certain
pathways.
effectiveness
ICIs
treating
adult
has
widely
acknowledged.
However,
results
early
phase
I/II
clinical
trials
that
exclusively
targeted
use
for
different
underwhelming.
rates
to
generally
modest,
except
cases
classic
Hodgkin
lymphoma.
There
seems
be
a
notable
disparity
immunogenicity
childhood
compared
cancers,
potentially
accounting
this
phenomenon.
On
average,
tend
significantly
fewer
neoantigens.
In
recent
times,
there
renewed
sense
optimism
regarding
potential
benefits
ICI
specific
groups
children
with
cancer.
initial
research,
individuals
diagnosed
hypermutated
SMARCB1-deficient
shown
remarkable
positive
outcomes
when
treated
therapies.
This
likely
due
underlying
biological
factors
promote
expression
neoantigens
inflammation
within
tumor.
Ongoing
are
diligently
assessing
cancer
patients
these
subsets.
review
aimed
analyze
safety
types
highly
advanced
malignancies.
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 6, 2024
Abstract
Immunotherapy
has
demonstrated
significant
potential
in
the
treatment
of
cancer
and
is
now
recommended
as
a
first-line
therapy
for
small
cell
lung
melanoma.
However,
novel
response
pattern
been
delineated,
characterized
by
an
abrupt
acceleration
tumor
growth
subsequent
to
immunotherapy.
These
unforeseen
adverse
events
are
denoted
hyper
progressive
disease
(HPD).
The
occurrence
HPD
observed
not
only
patients
undergoing
immunotherapy
but
also
those
receiving
chemotherapy,
albeit
with
comparatively
lower
frequency
within
chemotherapy
cohort.
In
management
metastatic
pancreatic
cancer,
combination
presents
promising
therapeutic
approach;
however,
there
remains
unresolved
question
regarding
association
between
this
HPD.
Herein,
we
present
case
report
59-year-old
patient
exhibiting
high
PD-1/PD-L1
expression
identified
through
next-generation
sequencing
data,
suggesting
efficacy
PD-1
Therefore,
administered
serplulimab
(a
anti-PD-1
antibody)
gemcitabine/nab-paclitaxel.
initially
exhibited
favorable
chemotherapy;
enlargement
deterioration
physical
condition
occurred.
To
our
knowledge,
first
reported
multiple
metastases
treated
using
therapy.
Based
on
case,
propose
cancer.
Cancers,
Год журнала:
2024,
Номер
16(16), С. 2848 - 2848
Опубликована: Авг. 15, 2024
Pancreatic
cancer
is
a
significant
challenge
in
oncology
due
to
its
aggressive
nature
and
complex
management,
leading
high
mortality
rates
dismally
low
5-year
survival
rate.
Approximately
85%
of
cases
manifest
as
adenocarcinoma,
while
endocrine
tumors
constitute
less
than
5%.
Borderline
resectable
locally
advanced
pancreatic
cancers
are
particularly
difficult
treat
vascular
involvement,
which
complicates
complete
resections
increases
morbidity.
Various
therapeutic
modalities
aim
overcome
these
challenges
improve
patient
outcomes.
Traditionally,
upfront
surgery
was
the
standard
for
tumors,
with
multimodal
chemotherapy
being
central
treatment.
Understanding
surgical
anatomy
pivotal
enhancing
outcomes
survival.
Resectability
several
when
seeking
achieve
R0
resections,
borderline
tumors.
classification
systems-the
MD
Anderson
criteria,
NCCN
AHPA/SSAT/SSO
consensus
statement,
Alliance
definition-assess
tumor
involvement
major
blood
vessels,
first
systems
broadly
accepted.
Vascular
staging
integration
also
important,
Ishikawa
system
using
preoperative
imaging
assess
venous
involvement.
Furthermore,
neoadjuvant
therapy
enhances
treatment
effectiveness
by
addressing
micro-metastatic
disease
early,
increasing
resection
chances,
downstaging
optimal
surgery.
Insights
from
Fox
Chase
Cancer
Center's
approach
highlight
importance
multidisciplinary
strategy
advancing
improving
prognosis.
This
commentary,
inspired
Dr.
Sanjay
S.
Reddy's
Keynote
Conference
during
MedNews
week,
highlights
current
advancements
ongoing
cancer,
emphasizing
need
comprehensive,
